🇺🇸 FDA
Company

enGene

enGene Therapeutics

ENGN biotech USA

Quick answer

enGene is a biotech company (ENGN) headquartered in SAINT-LAURENT, USA with 1 tracked pipeline programs.

Pipeline (1)

project

EG-70 (phase 1)

Superficial Bladder Cancer

Phase 2 · small_molecule · active

1 trials

Drugs (1)

drug

linvoseltamab-gcpt

LYNOZYFIC

Patents (8)

patent

US 12421273

Ectonucleotidase inhibitors and methods of use thereof

Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12414968

Compositions comprising bacterially derived minicells and methods of using the s

Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12357687

Compositions and vaccines for treating and/or preventing viral infections, and m

Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12337033

Encapsulated glycolipid antigens for treatment of neoplastic diseases

Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12076418

Dually derivatized chitosan nanoparticles and methods of making and using the sa

Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11964021

Bacterially derived, intact minicells for delivery of therapeutic agents to brai

Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11883433

Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof

Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11858957

Ectonucleotidase inhibitors and methods of use thereof

Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)